Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

Gunst JD
  NCT04321096		 RCTcamostat mesilateplaceboCOVID 19 all comerssome concern
139/69 inconclusive

    COVID-19 mild to moderate meta-analysis

    VERU-111
          NCT04842747    		 RCTsabizabulinplaceboCOVID-19 mild to moderatesome concern
    		134/70 conclusif
    • demonstrated 70 % decrease in 14-days deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
    Crippa (CANDIDATE)
          NCT04467918    		 RCTCannabidiolplaceboCOVID-19 mild to moderatesome concern
    		53/52 inconclusive

      COVID-19 severe or critically meta-analysis

      Fragoso-Saavedra (PISCO)
              NCT04343963      		 RCTpyridostigmineplaceboCOVID-19 severe or criticallysome concern
      		94/94 suggested
      • suggested 68 % decrease in death D28 with a moderate degree of certainty due to some concern in risk of bias
      • suggested 67 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 54 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons